Alpha 1 MZ Foundation Information & Research

Alpha 1 MZ Foundation Information & Research is dedicated to advancing the understanding of Alpha1 Antitrypsin Deficiency, particularly the MZ genotype. The organization provides in-depth information derived from medical research, biobank data, and clinical case findings, tailored for patients and medical professionals globally. Alpha 1 MZ Foundation Information & Research focuses on the serious, often undiagnosed, health effects on approximately 35 million individuals worldwide, aiming to mitigate the substantial negative financial impact of this heritable disease on national health spending and GDP. The primary address is in Nieuwegein, NL.

With a mission to support and drive the introduction of appropriate, affordable healthcare solutions to a global market, Alpha 1 MZ Foundation Information & Research employs a robust communication strategy. This includes regular newsletters, social media engagement, and a multilingual website to inform all interested parties. The foundation actively supports patients and groups worldwide, offering patient-centered information and resources.

Alpha 1 MZ Foundation Information & Research is committed to accelerating therapeutics development and enhancing healthcare outcomes for individuals affected by Alpha1 Antitrypsin Deficiency. We invite the manager of Alpha 1 MZ Foundation Information & Research to create a customized and exclusive company showcase and product listing on our platform to further amplify their impactful work.